Comparison of Antibiotic Sensitivity Pattern of Escherichia coli which Produce Extended Spectrum Beta-Lactamase Strains Isolated From Various Clinical Specimens In Intensive Care Unit
Abstract
Objective: A retrospective analysis of the widely used antibiotics all susceptibility testing results from Escherichia coli (E. coli) cultured from clinical specimens private hospital (from January 2017 to November 2018) was performed.
Methods: The VITEK 2 Compact automated microbiology system (bioMérieux) is designed for automated rapid antimicrobial susceptibility testing and identification of clinically relevant bacteria. Minimum inhibitory concentration (MIC) results previously obtained in recent clinical isolates with well-defined in isolates with well-characterized resistance mechanisms with the microdilution method were re-interpreted for the susceptible, intermediate and resistant categories using the 2018 EUCAST breakpoints. Clinical samples are most commonly isolated from blood, sputum and urine samples.
Results: The results of resistance pattern of E. coli isolates in our locality to antimicrobial agents showed that the 64 E. coli strains tested against fifteen antimicrobial agents. E. coli isolates were highly resistant to piperacillin, ceftazidime and aztreonam 98%, 61% and 61% respectively. The most sensitive antibiotics were colistin, tigecycline, imipenem and meropenem. In the present study, 73% (47) of the isolates were resistant to at least three to fourteen antibiotics. All of the isolates showed resistance to at least one antibiotics. Thirty nine per cent of E. coli isolates were extended spectrum beta-lactamase (ESBL) producers.
Conclusion: Considering the antibiogram, imipenem and meropenem should be preferred drugs
for E. coli infection isolated from
clinical samples.
Keywords
Esherichia coli,antibiotic sensitivity,clinical specimens,intensive care unit
References
- Abreu AG, Marques SG, Monteiro-Neto V, Carvalho RM, Goncalves AG. Nosocomial infection and characterization of extended-spectrum beta-lactamases-producing Enterobacteriaceae in Northeast Brazil. Rev Soc Bras Med Trop. 2011; 44(4) :441–6.
- Akter F, M. Mahboob Hossain, Arifur Rahman, Mukta Shaha and Amani El Abd Abu Amo Amani, Antimicrobials Resistance Pattern of Escherichia coli Collected from Various Pathological Specimens. Pakistan Journal of Biological Sciences 2012; 15: 1080-1084.
- Albayrak N, and S. Kaya. Extended spectrum beta lactamases production and antimicrobial resistance ratio of the Esherichia coli and Klebsiella pneumoniae strains isolated from various clinical specimens. Turkish Society of Microbiology Journal 2009; 39: 16–21.
- Al-Mijalli SHS. Bacterial Uropathogens in Urinary Tract in Riyadh Hospital, Saudi Arabia. Cell Mol Med 2017, 3:1.
- Ashgar, A. H. Frequency and antimicrobial susceptibility patterns of bacterial pathogens isolated from septisemic patients in Makkah hospitals. Saudi Medical Journal 2006; 27(3): 361-367.
- Apisarnthanarak A, Kiratisin P, Mundy LM. Predictors of mortality from community-onset bloodstream infections due to extendedspectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2008; 29(7): 671–4.
- Batarseh A, Soneah S, Mardeni R, Elmadni K, Noor M, Ashour NA. Antibiotic resistance patterns of multidrug resistant and extended-spectrum β -lactamase producing Esherichia coli urinary isolates at queen Rania al-abdullah hospital for children. Jordan Z U M J. 2013;19(5):286–93.
- Cappuccino, J.G., N. Sherman, Microbiology: A Laboratory Manual. 7th Edn., 2004. Pearson Education (Singapore), Indian Branch, New Delhi, ISBN: 080532836X pp: 544.
- Chander A, Shrestha CD. Prevalence of extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae urinary isolates in a tertiary care hospital in Kathmandu, Nepal. BMC ResNotes 2013; 6:487. doi: 10.1186/1756-0500-6-487.
- Daoud,Z., N. Hakime. Prevalence and susceptibility patterns of extended-spectrum beta-lactamaseproducing Escherichia coli and Klebsiella pneumoniae in a general university hospital in Beirut, Lebanon. Rev Esp Quimioter 2003; 16(2): 233-8.